Welcome to our dedicated page for Medtronic SEC filings (Ticker: MDT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Medtronic plc (NYSE: MDT) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, giving investors and analysts a detailed view of its financial condition, capital structure, governance, and material events. As an issuer with ordinary shares and multiple series of senior notes listed on the New York Stock Exchange, Medtronic files annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, proxy statements on Schedule 14A, and specialized forms such as Form 25 for the removal from listing of specific debt securities.
Medtronic’s Form 8-K filings cover topics such as quarterly financial results, debt offerings, redemptions of senior notes, amendments to its Memorandum and Articles of Association, changes in board composition and executive roles, and other material definitive agreements. For example, recent 8-Ks describe euro-denominated senior notes due 2030 and 2045, their guarantees by Medtronic plc and affiliates, and the use of proceeds to repay existing notes. Other current reports document National Coverage Determinations, financial guidance updates, and dividend-related actions referenced in company news releases.
The company’s proxy statements (DEF 14A) outline its corporate governance structure, director elections, executive compensation programs, and shareholder proposals, including amendments to Articles of Association and capital reduction measures under Irish law. Form 25 filings relate to the delisting of specific classes of guaranteed senior notes once they are redeemed or otherwise withdrawn from the exchange, and do not affect the listing of MDT ordinary shares.
On this page, Stock Titan pairs Medtronic’s filings with AI-powered summaries that highlight key points from lengthy documents, helping users quickly understand items such as new debt issuances, changes in capital structure, or governance amendments. You can review 10-K and 10-Q reports for segment performance and risk disclosures, scan 8-Ks for notable events, and monitor registration statements and S-1 filings, such as the proposed IPO of the MiniMed diabetes business, to follow Medtronic’s strategic and financial decisions over time.
The Vanguard Group filed Amendment No. 10 to a Schedule 13G/A regarding Medtronic PLC common stock, reporting 0 shares beneficially owned and 0% of the class. The filing explains an internal realignment effective January 12, 2026 under SEC Release No. 34-39538 that caused certain Vanguard subsidiaries or divisions to report holdings separately.
The statement is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026.
Medtronic plc reported that its subsidiary MiniMed Group received earlier-than-expected U.S. FDA clearance for the MiniMed Flex, a next-generation, smartphone-controlled insulin pump. The product’s research and development was partly funded by Blackstone Life Sciences under a deal that entitles Blackstone to mid-to-high single digit royalties or specified minimum payments for two years after U.S. approval and launch.
MiniMed expects to record a one-time charge of $157 million in Medtronic’s fourth quarter of fiscal 2026 for future payments to Blackstone, with an estimated $0.08 per share impact based on Medtronic’s 90% MiniMed ownership. Separately, the recent IPO of 10% of MiniMed is expected to dilute Medtronic shareholders by about $0.04 per share in that quarter.
As a result, Medtronic now guides full-year fiscal 2026 non-GAAP EPS to $5.50–$5.54, reduced from the prior $5.62–$5.66 range. Guidance for fiscal 2027 remains unchanged at high single-digit EPS growth and is based on the earlier, higher EPS baseline before these MiniMed-related items.
Medtronic plc filed a shelf registration under Form S-3 to permit the periodic offering of debt securities by Medtronic Global Holdings S.C.A. and Medtronic, Inc., to be offered "from time to time after this registration statement becomes effective."
The prospectus states debt issued by each issuer will be fully and unconditionally guaranteed on a joint and several basis by the other group members named, and that specific terms, amounts and distribution methods will be provided in prospectus supplements.
Medtronic plc filed an initial ownership report for MiniMed Group, Inc., stating indirect beneficial ownership of 252,813,348 shares of MiniMed common stock. This Form 3 does not report new share purchases or sales, but formally records Medtronic as a more than 10% owner.
Medtronic plc executive vice president and chief financial officer Thierry Pieton reported a tax-related share disposition tied to equity compensation. On the transaction date, 2,976 ordinary shares were withheld at a price of $96.71 per share to cover taxes upon the vesting of previously granted restricted stock units. After this withholding, Pieton directly held 37,574 Medtronic ordinary shares, which total includes 592 shares acquired through dividend reinvestment since his prior report.
Medtronic plc executive Harry Skip Kiil reported mixed equity transactions involving stock options and ordinary shares. On February 19, 2026, he exercised multiple stock options (rights to buy), converting them into ordinary shares at exercise prices reflected as $0.0000 per option in the derivative rows.
On the same date, he conducted several open-market sales of ordinary shares coded as "S," totaling 52,524 shares sold according to the transaction summary. Sale prices for these transactions include individual entries around $97.66 to $97.86, with a footnote stating a weighted average sale price and an actual range from $97.60 to $97.775.
Following these exercises and sales, his directly held ordinary share balance shown in the final row is 32,768 shares. A footnote also notes that this total includes 239 shares acquired through dividend reinvestment since his prior report.
Medtronic plc Chief Accounting Officer Denise L. Blomquist reported a bona fide gift of 340 Ordinary Shares of Medtronic on February 20, 2026. The gift was reported at a price of $0.00 per share, indicating no consideration was received for the transfer.
Following this charitable or personal gift transaction, Blomquist’s directly held stake stands at 11,966 Ordinary Shares of Medtronic. The filing reflects a disposition of shares through gifting rather than an open-market sale or purchase.
Medtronic plc reported fiscal Q3 2026 net sales of $9.0 billion, up from $8.3 billion a year earlier, driven by growth across Cardiovascular, Neuroscience, Medical Surgical, and Diabetes. Operating profit declined to $1.5 billion, and net income attributable to Medtronic fell to $1.1 billion, with diluted EPS at $0.89 versus $1.01.
For the first nine months, revenue reached $26.6 billion, up from $24.6 billion, while net income was roughly flat at $3.6 billion and diluted EPS was $2.76. Strong operating cash flow of $4.8 billion funded $2.7 billion in dividends and $0.6 billion of share repurchases, even as long‑term debt rose to $27.9 billion.
The company is preparing to separate its Diabetes business into MiniMed, an independent public company, and has launched a restructuring program expected to cost $300–$500 million through fiscal 2029. Medtronic also recorded higher restructuring and certain litigation charges and continued using derivative and funding arrangements to manage currency, interest rate, and development risks.
Filer reports proposed sale of Common stock via Form 144. The filing lists proposed dispositions of Common shares tied to restricted stock vesting and option exercises with transaction dates including 12/06/2025 and filing date 02/19/2026. Examples shown include Fidelity Brokerage Services LLC 52,524 and an individual grant-related lot of 30,568 shares.
Medtronic plc reported strong third quarter fiscal 2026 results, with revenue of $9.017 billion, up 8.7% as reported and 6.0% on an organic basis, slightly ahead of guidance.
GAAP diluted EPS was $0.89, while non-GAAP diluted EPS was $1.36, three cents above the guidance mid-point. Cardiovascular revenue rose 13.8% to $3.457 billion and Diabetes revenue grew 14.8% to $796 million, with Cardiac Ablation Solutions up 80% on strength in pulsed field ablation.
The company reiterated its FY26 organic revenue growth outlook of about 5.5% and non-GAAP EPS guidance of $5.62 to $5.66, including a possible $185 million tariff impact. Medtronic also highlighted multiple regulatory milestones, including U.S. FDA clearances for its Hugo robotic-assisted surgery system and Stealth AXiS Surgical System, CE Mark for Sphere-360, and two M&A deals in coronary, renal denervation, and structural heart.